Compare · EWTX vs NVO
EWTX vs NVO
Side-by-side comparison of Edgewise Therapeutics Inc. (EWTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EWTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 44.9x EWTX ($4.80B).
- EWTX has been more active in the news (18 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 16 for EWTX).
- Company
- Edgewise Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $4.80B
- $215.46B
- 1M return
- -
- -2.08%
- 1Y return
- -
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 18
- 9
- Recent ratings
- 16
- 25
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EWTX
- Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
- Amendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael
- Amendment: SEC Form 4 filed by CMO Donovan Joanne M.
- Amendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J
- Amendment: SEC Form 4 filed by General Counsel Moore John R
- Amendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad
- SEC Form 4 filed by Chief Financial Officer Nofi Michael
- General Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)
- CMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)
- Chief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S